


IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of claims:

Claim 1 (**currently amended**): A compound of formula (I):



wherein:

~~p is 0;~~

R^2 is amino, R^6 or R^6 -NH-;

R^3 is hydrogen, halo or cyano;

R^4 is C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-4} alkyl, or heterocyclyl;

R^5 is C_{1-6} alkyl or C_{2-6} alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy;

R^6 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, or (heterocyclic group) C_{1-3} alkyl; wherein R^6 may be optionally substituted on carbon by one or more methoxy, ethoxy or trifluoromethyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 2 (**cancelled**).

Claim 3 (**previously presented**): The compound of formula (I) according to claim 1 wherein R² is R⁶-NH- wherein R⁶ is C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl or (heterocyclic group)C₁₋₃alkyl; and wherein R⁶ may be optionally substituted on carbon by one methoxy, ethoxy or trifluoromethyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 (**previously presented**): The compound of formula (I) according to claim 1 wherein R³ is hydrogen; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claims 5-6 (**cancelled**).

Claim 7 (**currently amended**): The compound of formula (I) as claimed in claim 1 wherein:

p is 0;

R² is methylamino, allylamino, *t*-butylamino, 2-methoxyethylamino, 2-ethoxyethylamino, 3-methoxypropylamino, cyclopropylamino, cyclobutylamino, cyclopropylmethylamino, 2,2,2-trifluoroethylamino, tetrahydrofur-2-ylmethylamino or pyrid-2-ylmethylamino;

R³ is hydrogen;

R⁴ is cyclopropylmethyl, 2-cyclopropylethyl, cyclobutyl, cyclopropyl, cyclopentyl or tetrahydrofur-3-yl;

R⁵ is methyl, ethyl, propyl, methoxymethyl or 2-methylprop-1-enyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 8 (**previously presented**): The compound of formula (I) as claimed in claim 1 selected from:

4-(1-cyclopentyl-2-methylimidazol-5-yl)-2-{4-[*N*-(cyclopropyl)sulphamoyl]anilino} pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]
anilino}pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[N-(2,2,2-trifluoroethyl)sulphamoyl]
anilino}pyrimidine;

4-(1-cyclopropylmethyl-2-methylimidazol-5-yl)-2-{4-[N-(cyclobutyl)sulphamoyl]
anilino}pyrimidine;

4-(1-cyclopropylethyl-2-methylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]
anilino}pyrimidine;

4-(1-cyclopropylethyl-2-methylimidazol-5-yl)-2-{4-[N-(tetrahydrofurfur-2-ylmethyl)
sulphamoyl]anilino}pyrimidine;


4-(1-cyclopropylethyl-2-methoxymethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]
anilino}pyrimidine; and

4-(1-cyclopropylmethyl-2-ethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)
sulphamoyl]anilino}pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.


Claim 9 (**currently amended**): A process for preparing a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof which process (wherein R^1 , R^2 , R^3 , R^4 , R^5 and p are, unless otherwise specified, as defined in claim 1) comprises of:

Process a) reaction of a pyrimidine of formula (II):




(II)

wherein L is a displaceable group; with an aniline of formula (III):




or

Process b) reacting a compound of formula (IV):




with a compound of formula (V):



wherein T is O or S; R^x may be the same or different and is C_{1-6} alkyl;

Process c) for compounds of formula (I) where R^2 is amino or a group R^6 -NH-; reacting a pyrimidine of formula (VI):




wherein X is a displaceable group; with an amine of formula (VII):




(VII)

wherein R^a is hydrogen or R⁶;

Process d) reacting a pyrimidine of formula (VIII)




with a compound of formula (IX):



where Y is a displaceable group; or

Process e) for compounds of formula (I) wherein R² is R⁶; oxidising a compound of formula (X):



and thereafter optionally:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

Claim 10 (**currently amended**): A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1, ~~2-4~~ 3-4 and 7-8, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 11-13 (**cancelled**).

Claim 14 (**currently amended**): A method for the treatment of ~~solid-tumour-cancers and leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation,~~ which method comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1, 3-4 and 7-8.

Claims 15-20 (**cancelled**).